Publication date: Jul 02, 2019
An experimental drug for Huntington’s disease from Carlsbad’s Ionis Pharmaceuticals appears to be more long-lasting than previously thought.
Roche announced the trial’s resumption to the Huntington’s disease community on June 20, according to the blog of Kenneth Serbin, who carries the mutation.
New information from an earlier trial indicated that the drug, RG6042, showed the same signs of potential efficacy when given every two months, as when given every month.
“We believe this change to the pivotal study design will greatly simplify the operation of the study and ease the burden on study sites and patients, as less frequent dosing is more manageable for patients and physicians,” Frank Bennett, senior vice president of research at Ionis, said by email.
- Investigational IONIS-HTTRx Lowers Mutant Huntingtin Protein in Early-stage Patients, Phase 1/2 Data Show
- A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington’s Disease
- How the Gene-Silencing Studies Changed My Outlook on HD